Table 1.
Patient demographics and baseline characteristics of the matched population
| Characteristic | Low HOMA‐β Index (n = 273) | High HOMA‐β Index (n = 273) | P Value |
|---|---|---|---|
| HOMA‐β score | 18.5 (6.0) | 54.3 (71.2) | <.0001 |
| Age, years | 55.7 (9.6) | 55.8 (9.7) | .8453 |
| Sex, male/female, % | 52.8/47.3 | 54.2/45.8 | .7314 |
| Race, % | .3087 | ||
| Asian | 15.4 | 12.8 | |
| Black/African American | 3.3 | 3.3 | |
| White | 77.7 | 82.4 | |
| Other | 3.7 | 1.5 | |
| BMI, kg/m2 | 31.8 (6.1) | 32.4 (5.7) | .2102 |
| Known diabetes duration, years | 6.9 (4.4) | 7.4 (5.3) | .2460 |
| Duration of OAD therapy, years | 4.0 (3.5) | 4.6 (4.5) | .0899 |
| Metformin at baseline, % | 88.6 | 91.6 | .2514 |
| Sulphonylurea at baseline, % | 18.3 | 22.7 | .2034 |
| HbA1c, % | 8.1 (0.8) | 8.1 (0.9) | .8308 |
| PPG, mmol/L | 16.9 (3.9) | 15.3 (3.7) | .0012 |
| Glucose excursion, mmol/L | 7.0 (3.4) | 6.1 (3.1) | .0352 |
| FPG, mmol/L | 9.2 (1.7) | 9.3 (2.0) | .3910 |
Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; HOMA‐β, homeostasis model assessment of residual β‐cell function; OAD, oral antidiabetic drug; PPG, postprandial plasma glucose; SD, standard deviation.
Data are mean (SD) unless stated otherwise.